Selenium Distribution Pattern, Antineoplastic and Immunostimulatory Activities of a Novel Organoselenium Compound Eb

Abstract

Abstract: Aim To study the distribution pattern, antineoplastic activity and immunocompetence of a novel organoselenium compound Eb and investigate its in vivo antineoplastic potential. Methods Eb was administered to Kunming mice (dosage, 0.1 g·kg^-1·d^-1) intragastrically for 7 successive days. The contents of selenium in heart, liver, spleen, kidneys, lungs, stomach, brain, muscle, and bone were determined by fluorometric method on the eighth day. MTT assay was used to study tumor growth inhibition of Eb in vitro, and lymphocyte transformation, hemolysin formation and phagocytosis assay were used to study its immunocompetence. Results After 7 days, administration of Eb, the tissue contents of sele-(nium) in liver, spleen, lungs, kidneys, and bone of mice increased, especially those in liver and spleen increased significan-tly, compared with controls; but no significant changes of such contents were found in muscle, heart, brain, and stomach. Eb demonstrated inhibitory effects on human Bel-7402, BGC-823, and Calu-3 cancer cell lines in vitro. Eb also showed ability to enhance lymphocyte transformation and serum hemolysin formation in vitro and increase the phagocytosis of macrophages. Conclusion The validated antitumor and immunostimulatory activities of Eb suggest a hypothesis that Eb may behave as a biological response modifier when used as an antitumor agent. Eb is worthy of further study in developing a new antineoplastic and immunity enhancing agent in the light of its antitumor activity, immunocompetence and specific distribution in liver, lungs, kidneys, bone, and spleen.

Key words: Organoselenium compound, Organoselenium compound, tissue distribution, tissue distribution, antitumoral activity, antitumoral activity, immunocompetence, immunocompetence

CLC Number:

R962

R979.1

Supporting:

YAN Jun, DENG Sheng-ju, KUANG Bin, HE Fei, LIU Tao, ZENG Hui-hui^*. Selenium Distribution Pattern, Antineoplastic and Immunostimulatory Activities of a Novel Organoselenium Compound Eb[J]. .

References

[1] Das A, Desai D, Pittman B, et al. Comparison of the chemopreventive efficacies of 1,4-phenylenebis (methylene) selenocyanate and selenium-enriched yeast on 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone induced lung tumorigenesis in A/J mouse [J]. Nutr Cancer, 2003, 46: 179-185.
[2] Schrauzer GN. Cancer mortality correlation studies-III: statistical associations with dietary selenium intakes [J]. Bioinorg Chem, 1977, 5: 23-24.
[3] Wang L, Ling R,Geng J. The distribution and meaning of trace element selenium and oxygen radical in primary breast cancer [J]. J Fourth Milit Med Univ, 1995, 16 (1): 15-15.
[4] Musik I, Koziol-Montewka M, Tos-Luty S, et al. Comparison of selenium distribution in mice organs after the supplementation with inorganic and organic selenium compound selenosemicarbazide [J]. Ann Univ Mariae Curie Sklodowska, 2002, 57: 15-22.
[5] Jastrzebski Z, Czyzewska-Szafran H, Remiszewska M, et al. Pharmacokinetics of selol, a new agent containing selenium in rats [J]. Drugs Exp Clin Res, 1997, 23: 7-11.
[6] Liu Q, Analysis and determination of selenium [A]. In: Xu HB, Huang KX, ed. Selenium: Its chemistry, biochemistry and application in life science [M]. Wuhan: Publishing House of Huazhong Science and Technology University, 1994. 80-86.
[7] Tang QH, Sun Y, Zhou JM, et al. Determination of selenium in serum by 2,3-diaminonaphthalene fluoroscopy[J]. Clin Inspec, 1994, 12: 186-187.
[8] Shi CJ, Yu LZ, Yang FG, et al. A novel organoselenium compound induces cell cycle arrest and apoptosis in prostate cancer cell lines [J]. Biochem Biophys Res Commun, 2003, 309: 578-583.
[9] Wang YR, Zeng HH. The investigation of anticarcinogenic action of BBSKE, a novel organoselenium compound, in inhibiting on growth and metastasis of surgically transplanted Lewis lung cancer [J]. J Peking Univ (Health Sci), in press.
[10] Shi CJ, Zeng HH, Li HW, et al. Induction of apoptosis in prostate cancer cell line PC-3 by BBSKE, a novel organoselenium compound, and its effect in vivo [J]. Natl Med J China, 2003, 83: 1984-1988.

[1]	Zhenzhen Wu, Hengchun Ren, Yanying Li, Jiajia Fu, Xiaojun Liu, Jie Hu. Tissue distribution and pharmacokinetics of brucine niosomal gels in rats after topical and oral application [J]. Journal of Chinese Pharmaceutical Sciences, 2018, 27(2): 92-98.
[2]	Aixia Ju, Yuhong Kang, Qingdan Xue, Qiuhong Li. Pharmacokinetics, tissue distribution and excretion study of tetrandrine in rats [J]. Journal of Chinese Pharmaceutical Sciences, 2015, 24(8): 557-562.
[3]	Yu-Feng Xia^*, Yue Dai, Hui-Zhen Liang . Studies on tissue distribution and excretion of scopoletin after oral administration in rats [J]. , 2012, 21(2): 149-155.
[4]	Ye-Huan Li, Guo-Zhou Zhang, Rong-Hua Huang, Dong-Dong Li, Yu Luo, Yong Yang, Yin-Qun Wu, Li-Hui Liu, Hui-Hui Zeng^*. Study on tissue distribution of a novel organoselenium antitumor compound WBSELEN [J]. , 2011, 20(6): 578-583.
[5]	Chong Yan, Li Lin^*, Hong-Ju Liu, Yan-Jiao Zhang, Ya-Hui Chen. Study on pharmacokinetic and tissue distribution of isovitexin in rats by HPLC [J]. , 2011, 20(4): 376-382.
[6]	Jin-Ping Wang, Xia-Li Zhu, Yan-Wei Xi, De-Feng Wang, Gui-Hua Huang^*. Preparation of lomustine loaded liposomes and studies of its pharmacokinetics and tissue distribution properties [J]. , 2010, 19(5): 353-362.
[7]	Jia-Ning Fu, Jing-Yu Wang, Li-Hui Wang, Lei Wang, Wan-Chen Tang, Gao-Xiong Cai, Mi Liu, Hui-Hui Zeng^* . Drug efficacy and pharmacological action of an organoselenium compound ethaselen, a novel antitumor drug [J]. , 2010, 19(3): 163-168.
[8]	Jia-Yu Zhou, Zhi-Yun Meng, Gui-Fang Dou*, Shou-Ting Fu, Zi-Chun Hua, Xiang Yang, Jun Liu, Li-Jun Wei, Sun-Hua Zhang. Tissue distribution, excretion and pharmacokinetics of R-hap in rats [J]. , 2008, 17(2): 106-112.
[9]	YE Min^*, ZHU Zhu, FU Qiang, SUN Qiang, MAO Feng. Tissue Penetration of Capecitabine and Its Tumor-Selective Delivery of 5-FU in Advanced Breast Cancer Patients [J]. , 2006, 15(3): 131-138.
[10]	ZHANG Xiao-bin, HOU Xin-pu^*. Comparative Efficacy and Distribution of Evans Blue Liposome Modified with DSPE-PEG, Tween80, and Brij35 [J]. , 2003, 12(2): 71-75.
[11]	Lu Wanliang, Wei Shuli, Zhang Qiang, Qi Xianrong, Sun Huadong . Doxorubicin Stealth Liposomes Prepared with PEG-Distearoyl Phosphatidylethanolamine and Distribution as well as Antitumor Activity in Mice [J]. , 2000, 9(4): 191-195.